These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 21537380)

  • 21. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
    Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
    Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients.
    Carvalho B; Lopes RG; Linhares P; Costa A; Caeiro C; Fernandes AC; Tavares N; Osório L; Vaz R
    J Neurooncol; 2020 Mar; 147(1):109-116. PubMed ID: 31974803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria.
    Sugimoto H; Hamano Y; Charytan D; Cosgrove D; Kieran M; Sudhakar A; Kalluri R
    J Biol Chem; 2003 Apr; 278(15):12605-8. PubMed ID: 12538598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer.
    Feliu J; Salud A; Safont MJ; García-Girón C; Aparicio J; Losa F; Bosch C; Escudero P; Casado E; Jorge M; Bohn U; Pérez-Carrión R; Carmona A; Custodio AB; Maurel J
    PLoS One; 2015; 10(1):e0116527. PubMed ID: 25602286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cumulative dose of bevacizumab associates with albuminuria rather than podocyturia in cancer patients.
    Lankhorst S; Baelde HJ; Verstijnen JAMC; Ten Tije AJ; Thelen MHM; Danser AHJ; van den Meiracker AH; Kappers MHW
    J Am Soc Hypertens; 2018 Nov; 12(11):e1-e7. PubMed ID: 29960864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Worsening of renal function and uncontrolled hypertension from intravitreal bevacizumab injections.
    Ahmed M; Alouch N; Ahmed A; Jagadesh SK
    Proc (Bayl Univ Med Cent); 2021 Mar; 34(4):527-529. PubMed ID: 34219948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management.
    Izzedine H; Massard C; Spano JP; Goldwasser F; Khayat D; Soria JC
    Eur J Cancer; 2010 Jan; 46(2):439-48. PubMed ID: 20006922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of Proteinuria in Patients Receiving Anti-VEGF Therapy for Advanced Colorectal Cancer].
    Kinugasa S; Horikawa M; Kawashima T; Monma H; Hori H; Kobayashi I; Takase S
    Gan To Kagaku Ryoho; 2019 Aug; 46(8):1334-1336. PubMed ID: 31501383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of cyclosporin A on glomerular barrier function in the nephrotic syndrome.
    Zietse R; Wenting GJ; Kramer P; Schalekamp MA; Weimar W
    Clin Sci (Lond); 1992 Jun; 82(6):641-50. PubMed ID: 1320544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
    Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
    Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravitreal Antivascular Endothelial Growth Factor Therapy May Induce Proteinuria and Antibody Mediated Injury in Renal Allografts.
    Cheungpasitporn W; Chebib FT; Cornell LD; Brodin ML; Nasr SH; Schinstock CA; Stegall MD; Amer H
    Transplantation; 2015 Nov; 99(11):2382-6. PubMed ID: 25905984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies.
    Jones SF; Spigel DR; Yardley DA; Thompson DF; Burris HA
    Clin Adv Hematol Oncol; 2011 Nov; 9(11):845-52. PubMed ID: 22252616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing the dose and schedule of anti-vascular endothelial growth factor antibodies in non-small-cell lung cancer.
    Klamerus JF; Brahmer JR
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S51-6. PubMed ID: 21884999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Self-limited membranous nephropathy after intravitreal bevacizumab therapy for age-related macular degeneration.
    Khneizer G; Al-Taee A; Bastani B
    J Nephropathol; 2017 Jul; 6(3):134-137. PubMed ID: 28975092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of vascular endothelial growth factor and its receptors in rats with protein-overload nephrosis.
    Horita Y; Miyazaki M; Koji T; Kobayashi N; Shibuya M; Razzaque MS; Cheng M; Ozono Y; Kohno S; Taguchi T
    Nephrol Dial Transplant; 1998 Oct; 13(10):2519-28. PubMed ID: 9794554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bevacizumab and ovarian cancer.
    Sato S; Itamochi H
    Curr Opin Obstet Gynecol; 2012 Feb; 24(1):8-13. PubMed ID: 22123222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of proteinuria monitoring practice patterns and treatment implications in patients with cancer receiving bevacizumab products.
    Sturgill K; Dicke K; Zangardi M; Osborne K
    J Oncol Pharm Pract; 2023 Sep; ():10781552231198779. PubMed ID: 37654248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bevacizumab increases risk for severe proteinuria in cancer patients.
    Wu S; Kim C; Baer L; Zhu X
    J Am Soc Nephrol; 2010 Aug; 21(8):1381-9. PubMed ID: 20538785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence.
    Hanna RM; Barsoum M; Arman F; Selamet U; Hasnain H; Kurtz I
    Kidney Int; 2019 Sep; 96(3):572-580. PubMed ID: 31229276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.